


Mapping viral hepatitis

- CHB prevalence, care, treatment; CHC prevalence and treatment; liver cancer
 - By PHN and SA3
- Collation of multiple data sources:
 - For prevalence: population-specific seroprevalence (CHB) and notifications (CHC)
 - For care and treatment: Medicare MBS and PBS
- Cascades of care by region
- High priority areas and populations
- Track progress

1. Trends in hepatitis C treatment



26

0.0%

5.0%

10.0%

2016 uptake (%) 2017 uptake (%)

15.0%

20.0%

25.0%


30.0%

35.0%

40.0%


Darling Downs and West Moreton 24 Murrumbidgee 29 Northern Territory 30 Western Queensland 31

1. Trends in hepatitis C treatment




Treatment utpake and rank 2016 and 2017, by PHN


1. Trends in hepatitis C treatment




2. Gaps in the CHB monitoring cascade




3. Disparities between monitoring and prescribing



3. Disparities between monitoring and prescribing



4. Representation of work from priority regions




Acknowledgements

- Epidemiology team, The Doherty Institute
- ASHM, partners in Mapping Project
- Department of Health, Australian Government
- Department of Human Services, Australian Government
- National Notifiable Diseases Surveillance System
- WHO CC VH Research Advisory Group
- Simon Graham, Praveena Gunaratnam
- Individuals who provided review and data
 - Kelly Hosking and Geoff Stewart, Simon Graham, Josh Hanson

Explore the portal:

https://ashm.org.au/programs/Viral-Hepatitis-Mapping-Project/



The Peter Doherty Institute for Infection and Immunity A joint venture between The University of Melbourne and The Royal Melbourne Hospital